Pairnomix’ efforts to bring precision medicine to the epilepsy community was featured in the April edition of the American Journal of Medical Genetics Part A. The article explores the company’s mission to provide personalized genetic research to an underserved market, namely individuals diagnosed with epilepsy due to identified, causative genetic mutations. Some researchers believe that one or more genetic factors may account for as many as 70% to 80% of epilepsy cases. Read more here.
Note: Further use of any Wiley content that appears on this website is strictly prohibited without permission from John Wiley & Sons, Inc. For more information, please contact email@example.com or call 1-978-646-2777.